From Sept. 18-20, the prestigious "CRO-Aviano MD Anderson Symposium on Precision Oncology" was held. Precision oncology is at the frontier of medical science, proposing a future where cancer treatments will be tailored to the genetic and molecular specificities of each individual patient.
The Aviano Oncology Reference Center, a pioneer in this field, has been collaborating for years with the MD Anderson Cancer Center in Houston, recently named the world's best center for research and treatment in oncology according to Newsweek rankings. This union has led to the creation of a restigious symposium held under the guidance of scientific curator Professor Gustavo Baldassarre, which represents an important moment of exchange among experts in the field.
In this context, IRS proudly announced the participation of Isabella Bondani, who presented at the Young Investigator Meeting a poster entitled:
"Advancements in Personalized Chemotherapy: Leveraging Microfluidic Technologies for Patient Cellular Response Analysis and Automated Real Time Screening without Reagents."
The abstract highlights an innovative microfluidic platform for personalized chemotherapy evaluation with customized image analysis supported by artificial intelligence.
In summary, the event demonstrated how the synergy between institutions and the dedication of researchers, such as Isabella Bondani, are charting a new era in precision oncology.
